Abstract:Epithelial-to-mesenchymal transitions (EMTs) are phenotypic plasticity processes that confer migratory and invasive properties to epithelial cells during development, wound-healing, fibrosis and cancer<a href="#ref-CR1">1</a>,<a href="#ref-CR2">2</a>,<a href="#ref-CR3">3</a>,<a href="/articles/s41586-019-1897-5#ref-CR4">4</a>. EMTs are driven by SNAIL, ZEB and TWIST transcription factors<a href="/articles/s41586-019-1897-5#ref-CR5">5</a>,<a href="/articles/s41586-019-1897-5#ref-CR6">6</a> together with microRNAs that balance this regulatory network<a href="/articles/s41586-019-1897-5#ref-CR7">7</a>,<a href="/articles/s41586-019-1897-5#ref-CR8">8</a>. Transforming growth factor β (TGF-β) is a potent inducer of developmental and fibrogenic EMTs<a href="/articles/s41586-019-1897-5#ref-CR4">4</a>,<a href="/articles/s41586-019-1897-5#ref-CR9">9</a>,<a href="/articles/s41586-019-1897-5#ref-CR10">10</a>. Aberrant TGF-β signalling and EMT are implicated in the pathogenesis of renal fibrosis, alcoholic liver disease, non-alcoholic steatohepatitis, pulmonary fibrosis and cancer<a href="/articles/s41586-019-1897-5#ref-CR4">4</a>,<a href="/articles/s41586-019-1897-5#ref-CR11">11</a>. TGF-β depends on RAS and mitogen-activated protein kinase (MAPK) pathway inputs for the induction of EMTs<a href="#ref-CR12">12</a>,<a href="#ref-CR13">13</a>,<a href="#ref-CR14">14</a>,<a href="#ref-CR15">15</a>,<a href="#ref-CR16">16</a>,<a href="#ref-CR17">17</a>,<a href="#ref-CR18">18</a>,<a href="/articles/s41586-019-1897-5#ref-CR19">19</a>. Here we show how these signals coordinately trigger EMTs and integrate them with broader pathophysiological processes. We identify RAS-responsive element binding protein 1 (RREB1), a RAS transcriptional effector<a href="/articles/s41586-019-1897-5#ref-CR20">20</a>,<a href="/articles/s41586-019-1897-5#ref-CR21">21</a>, as a key partner of TGF-β-activated SMAD transcription factors in EMT. MAPK-activated RREB1 recruits TGF-β-activated SMAD factors to SNAIL. Context-dependent chromatin accessibility dictates the ability of RREB1 and SMAD to activate additional genes that determine the nature of the resulting EMT. In carcinoma cells, TGF-β–SMAD and RREB1 directly drive expression of SNAIL and fibrogenic factors stimulating myofibroblasts, promoting intratumoral fibrosis and supporting tumour growth. In mouse epiblast progenitors, Nodal–SMAD and RREB1 combine to induce expression of SNAIL and mesendoderm-differentiation genes that drive gastrulation. Thus, RREB1 provides a molecular link between RAS and TGF-β pathways for coordinated induction of developmental and fibrogenic EMTs. These insights increase our understanding of the regulation of epithelial plasticity and its pathophysiological consequences in development, fibrosis and cancer.

TGF-β–induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops

Coupled Reversible and Irreversible Bistable Switches Underlying TGF-β-induced Epithelial to Mesenchymal Transition

Visualizing Dynamic Changes During TGF-β-Induced Epithelial to Mesenchymal Transition.

Investigating epithelial-to-mesenchymal transition with integrated computational and experimental approaches

Data‐ and theory‐driven approaches for understanding paths of epithelial–mesenchymal transition

TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis

Synergistic action of master transcription factors controls epithelial-to-mesenchymal transition

Distinguishing mechanisms underlying EMT tristability

TGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1

MicroRNA-182 Targets SMAD7 to Potentiate TGFβ-induced Epithelial-Mesenchymal Transition and Metastasis of Cancer Cells.

Inference of Intercellular Communications and Multilayer Gene-Regulations of Epithelial–Mesenchymal Transition From Single-Cell Transcriptomic Data

Mechanotactic Activation of TGF‐β by PEDOT Artificial Microenvironments Triggers Epithelial to Mesenchymal Transition

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.

Epithelial-mesenchymal Transition of Type Ⅱ Alveolar Epithelial Cells Induced by TGF-β1

TGFβ Selects for Pro‐stemness over Pro‐invasive Phenotypes During Cancer Cell Epithelial–mesenchymal Transition

Signal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their Crosstalks

Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway

Hysteresis Control of Epithelial-Mesenchymal Transition Dynamics Conveys a Distinct Program with Enhanced Metastatic Ability

Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor β

Signaling mechanisms of the epithelial-mesenchymal transition

Epithelial–mesenchymal transition and its transcription factors